Biotinylated N-acetyllactosamine-and N,N-diacetyllactosamine-based oligosaccharides as novel ligands for human galectin-3

Bioengineering

Volumn 4, Issue 2, 2017, Pages

  Böcker, Sophia ^a   Elling, Lothar ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Biotin; Chemo enzymatic synthesis; Galectin 3; LacdiNAc; Neo glycoprotein

Indexed keywords

EID: 85041109580     PISSN: None     EISSN: 23065354     Source Type: Journal    
DOI: 10.3390/bioengineering4020031     Document Type: Article

References (79)

1. Collins, B.E.; Paulson, J.C. Cell surface biology mediated by low affinity multivalent protein–glycan interactions. Curr. Opin. Chem. Biol. 2004, 8, 617–625.
2. Gabius, H.-J. Cell surface glycans: The why and how of their functionality as biochemical signals in lectin-mediated information transfer. Crit. Rev. Immunol. 2006, 26, 43–79.
3. Gabius, H.-J. The magic of the sugar code. Trends Biochem. Sci. 2015, 40, 341.
4. Sasisekharan, R.; Myette, J.R. The sweet science of glycobiology: Complex carbohydrates, molecules that are particularly important for communication among cells, are coming under systematic study. Am. Sci. 2003, 91, 432–441.
5. Lis, H.; Sharon, N. Lectins: Carbohydrate-specific proteins that mediate cellular recognition. Chem. Rev. 1998, 98, 637–674.
6. Monsigny, M.; Mayer, R.; Roche, A.-C. Sugar-lectin interactions: Sugar clusters, lectin multivalency and avidity. Carbohydr. Lett. 2000, 4, 35–52.
7. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature 1997, 387, 569–572.
8. Sharon, N. Bacterial lectins, cell-cell recognition and infectious disease. FEBS Lett. 1987, 217, 145–157.
9. Alvarez, C.P.; Lasala, F.; Carrillo, J.; Muñiz, O.; Corbí, A.L.; Delgado, R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by ebola virus in cis and in trans. J. Virol. 2002, 76, 6841–6844.
10. Danguy, A.; Camby, I.; Kiss, R. Galectins and cancer. BBA Gen. Subj. 2002, 1572, 285–293.
11. Rabinovich, G.A. Galectins: An evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ. 1999, 6, 711–721.
12. Nangia-Makker, P.; Honjo, Y.; Sarvis, R.; Akahani, S.; Hogan, V.; Pienta, K.J.; Raz, A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156, 899–909.
13. Dumic, J.; Dabelic, S.; Flögel, M. Galectin-3: An open-ended story. BBA Gen. Subj. 2006, 1760, 616–635.
14. Hittelet, A.; Legendre, H.; Nagy, N.; Bronckart, Y.; Pector, J.C.; Salmon, I.; Yeaton, P.; Gabius, H.J.; Kiss, R.; Camby, I. Upregulation of galectins-1 and-3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer 2003, 103, 370–379.
15. Hsu, D.K.; Dowling, C.A.; Jeng, K.C.G.; Chen, J.T.; Yang, R.Y.; Liu, F.T. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int. J. Cancer 1999, 81, 519–526.
16. Liu, F.-T.; Rabinovich, G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5, 29–41.
17. Krześlak, A.; Lipińska, A. Galectin-3 as a multifunctional protein. Cell. Mol. Biol. Lett. 2004, 9, 305–328.
18. Nakahara, S.; Oka, N.; Raz, A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10, 267–275.
19. Takenaka, Y.; Fukumori, T.; Raz, A. Galectin-3 and metastasis. Glycoconj. J. 2002, 19, 543–549.
20. Moon, B.-K.; Lee, Y.J.; Battle, P.; Jessup, J.M.; Raz, A.; Kim, H.-R.C. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: Implication of galectin-3 function during metastasis. Am. J. Pathol. 2001, 159, 1055–1060.
21. Johnson, K.D.; Glinskii, O.V.; Mossine, V.V.; Turk, J.R.; Mawhinney, T.P.; Anthony, D.C.; Henry, C.J.; Huxley, V.H.; Glinsky, G.V.; Pienta, K.J. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007, 9, 662–670.
22. Nangia-Makker, P.; Nakahara, S.; Hogan, V.; Raz, A. Galectin-3 in apoptosis, a novel therapeutic target. J. Bioenerg. Biomembr. 2007, 39, 79–84.
23. Mirandola, L.; Nguyen, D.D.; Rahman, R.L.; Grizzi, F.; Yuefei, Y.; Figueroa, J.A.; Jenkins, M.R.; Cobos, E.; Chiriva-Internati, M. Anti-galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer? Int. Rev. Immunol. 2014, 33, 417–427.
24. Salameh, B.A.; Leffler, H.; Nilsson, U.J. 3-(1, 2, 3-triazol-1-yl)-1-thio-galactosides as small, efficient, and hydrolytically stable inhibitors of galectin-3. Bioorg. Med. Chem. Lett. 2005, 15, 3344–3346.
25. Sörme, P.; Qian, Y.; Nyholm, P.G.; Leffler, H.; Nilsson, U.J. Low micromolar inhibitors of galectin-3 based on 3′-derivatization of N-acetyllactosamine. Chembiochem. 2002, 3, 183–189.
26. Ahmad, N.; Gabius, H.J.; Andre, S.; Kaltner, H.; Sabesan, S.; Roy, R.; Liu, B.C.; Macaluso, F.; Brewer, C.F. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 2004, 279, 10841–10847.
27. Nieminen, J.; Kuno, A.; Hirabayashi, J.; Sato, S. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J. Biol. Chem. 2007, 282, 1374–1383.
28. Ochieng, J.; Green, B.; Evans, S.; James, O.; Warfield, P. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. BBA Gen. Subj. 1998, 1379, 97–106.
29. Šimonová, A.; Kupper, C.E.; Böcker, S.; Müller, A.; Hofbauerová, K.; Pelantová, H.; Elling, L.; Křen, V.; Bojarová, P. Chemo-enzymatic synthesis of LacdiNAc dimers of varying length as novel galectin ligands. J. Mol. Catal. B Enzym. 2014, 101, 47–55.
30. Breloy, I.; Söte, S.; Ottis, P.; Bonar, D.; Grahn, A.; Hanisch, F.-G. O-linked LacdiNAc-modified glycans in extracellular matrix glycoproteins are specifically phosphorylated at the subterminal GlcNAc. J. Biol. Chem. 2012, 287, 18275–18286.
31. Kenny, D.T.; Skoog, E.C.; Lindén, S.K.; Struwe, W.B.; Rudd, P.M.; Karlsson, N.G. Presence of terminal N-acetylgalactosamineβ1–4N-acetylglucosamine residues on O-linked oligosaccharides from gastric MUC5AC: Involvement in Helicobacter pylori colonization? Glycobiology 2012, 22, 1077–1085.
32. Sasaki, N.; Shinomi, M.; Hirano, K.; Ui-Tei, K.; Nishihara, S. LacdiNAc (GalNAcβ1–4GlcNAc) contributes to self-renewal of mouse embryonic stem cells by regulating leukemia inhibitory factor/STAT3 signaling. Stem Cells 2011, 29, 641–650.
33. Van den Berg, T.K.; Honing, H.; Franke, N.; van Remoortere, A.; Schiphorst, W.; Liu, F.T.; Deelder, A.M.; Cummings, R.D.; Hokke, C.H.; van Die, I. LacdiNAc-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. J. Immunol. 2004, 173, 1902–1907.
34. Wuhrer, M.; Koeleman, C.A.M.; Deelder, A.M.; Hokke, C.H. Repeats of LacdiNAc and fucosylated LacdiNAc on N-glycans of the human parasite Schistosoma mansoni. FEBS J. 2006, 273, 347–361.
35. Fukushima, K.; Satoh, T.; Baba, S.; Yamashita, K. Α1, 2-fucosylated and β-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 2010, 20, 452–460.
36. Kaya, T.; Kaneko, T.; Kojima, S.; Nakamura, Y.; Ide, Y.; Ishida, K.; Suda, Y.; Yamashita, K. High-sensitivity immunoassay with surface plasmon field-enhanced fluorescence spectroscopy using a plastic sensor chip: Application to quantitative analysis of total prostate-specific antigen and GalNAcβ1–4GlcNAc-linked prostate-specific antigen for prostate cancer diagnosis. Anal. Chem. 2015, 87, 1797–1803.
37. Böcker, S.; Laaf, D.; Elling, L. Galectin binding to neo-glycoproteins: LacdiNAc conjugated BSA as ligand for human galectin-3. Biomolecules 2015, 5, 1671–1696.
38. Kupper, C.E.; Rosencrantz, R.R.; Henssen, B.; Pelantová, H.; Thönes, S.; Drozdova, A.; Křen, V.; Elling, L. Chemo-enzymatic modification of poly-N-acetyllactosamine (LacNAc) oligomers and N,N-diacetyllactosamine (LacdiNAc) based on galactose oxidase treatment. Beilstein J. Org. Chem. 2012, 8, 712–725.
39. Sörme, P.; Kahl-Knutsson, B.; Wellmar, U.; Magnusson, B.-G.; Leffler, H.; Nilsson, U.J. Design and synthesis of galectin inhibitors. Methods Enzymol. 2003, 363, 157–169.
40. Cumpstey, I.; Sundin, A.; Leffler, H.; Nilsson, U.J. C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: Efficient lectin inhibition through double arginine– arene interactions. Angew. Chem. 2005, 117, 5240–5242.
41. Kupper, C.E.; Böcker, S.; Liu, H.L.; Adamzyk, C.; van de Kamp, J.; Recker, T.; Lethaus, B.; Jahnen-Dechent, W.; Neuss, S.; Müller-Newen, G.; et al. Fluorescent SNAP-tag galectin fusion proteins as novel tools in glycobiology. Curr. Pharm. Des. 2013, 19, 5457–5467.
42. Witten, K.G.; Rech, C.; Eckert, T.; Charrak, S.; Richtering, W.; Elling, L.; Simon, U. Glyco-DNA–gold nanoparticles: Lectin-mediated assembly and dual-stimuli response. Small 2011, 7, 1954–1960.
43. Wurm, F.R.; Klok, H.A. Be squared: Expanding the horizon of squaric acid-mediated conjugations. Chem. Soc. Rev. 2013, 42, 8220–8236.
44. Tietze, L.F.; Arlt, M.; Beller, M.; Glüsenkamp, K.-H.; Jähde, E.; Rajewsky, M.F. Anticancer agents, 15. Squaric acid diethyl ester: A new coupling reagent for the formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides and diamides. Chem. Ber. 1991, 124, 1215–1221.
45. Hou, S.J.; Saksena, R.; Kovac, P. Preparation of glycoconjugates by dialkyl squarate chemistry revisited. Carbohydr. Res. 2008, 343, 196–210.
46. Roth, Z.; Yehezkel, G.; Khalaila, I. Identification and quantification of protein glycosylation. Int. J. Carbohydr. Chem. 2012, 2012, 1–10.
47. Jahouh, F.; Xu, P.; Vann, W.F.; Kovac, P.; Banoub, J.H. Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of Vibrio cholerae, serotype ogawa and the recombinant tetanus toxin C-fragment carrier. J. Mass Spectrom. 2013, 48, 1083–1090.
48. Wang, H.; Huang, W.; Orwenyo, J.; Banerjee, A.; Vasta, G.R.; Wang, L.X. Design and synthesis of glycoprotein-based multivalent glyco-ligands for influenza hemagglutinin and human galectin-3. Bioorg. Med. Chem. 2013, 21, 2037–2044.
49. Zou, J.; Glinsky, V.V.; Landon, L.A.; Matthews, L.; Deutscher, S.L. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 2005, 26, 309–318.
50. Song, X.Z.; Xia, B.Y.; Stowell, S.R.; Lasanajak, Y.; Smith, D.F.; Cummings, R.D. Novel fluorescent glycan microarray strategy reveals ligands for galectins. Chem. Biol. 2009, 16, 36–47.
51. Stowell, S.R.; Arthur, C.M.; Mehta, P.; Slanina, K.A.; Blixt, O.; Leffler, H.; Smith, D.F.; Cummings, R.D. Galectin-1,-2, and-3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 2008, 283, 10109–10123.
52. Stowell, S.R.; Dias-Baruffi, M.; Penttila, L.; Renkonen, O.; Nyame, A.K.; Cummings, R.D. Human galectin-1 recognition of poly-N-acetyllactosamine and chimeric polysaccharides. Glycobiology 2004, 14, 157–167.
53. Leppänen, A.; Stowell, S.; Blixt, O.; Cummings, R.D. Dimeric galectin-1 binds with high affinity to alpha 2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J. Biol. Chem. 2005, 280, 5549–5562.
54. Rapoport, E.M.; Andre, S.; Kurmyshkina, O.V.; Pochechueva, T.V.; Severov, V.V.; Pazynina, G.V.; Gabius, H.J.; Bovin, N.V. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: A case study on galectins-1 and-3 and the impact of assay setting. Glycobiology 2008, 18, 315–324.
55. Lopez-Lucendo, M.F.; Solis, D.; Andre, S.; Hirabayashi, J.; Kasai, K.; Kaltner, H.; Gabius, H.J.; Romero, A. Growth-regulatory human galectin-1: Crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J. Mol. Biol. 2004, 343, 957–970.
56. Di Virgilio, S.; Glushka, J.; Moremen, K.; Pierce, M. Enzymatic synthesis of natural and C-13 enriched linear poly-N-acetyllactosamines as ligands for galectin-1. Glycobiology 1999, 9, 353–364.
57. Qun, Z.; Cummings, R.D. L-14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch. Biochem. Biophys. 1993, 300, 6–17.
58. Diehl, C.; Engstrom, O.; Delaine, T.; Hakansson, M.; Genheden, S.; Modig, K.; Leffler, H.; Ryde, U.; Nilsson, U.J.; Akke, M. Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3. J. Am. Chem. Soc. 2010, 132, 14577–14589.
59. Seetharaman, J.; Kanigsberg, A.; Slaaby, R.; Leffler, H.; Barondes, S.H.; Rini, J.M. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-angstrom resolution. J. Biol. Chem. 1998, 273, 13047–13052.
60. Lobsanov, Y.D.; Gitt, M.A.; Leffler, H.; Barondes, S.H.; Rini, J.M. X-ray crystal structure of the human dimeric S-Lac lectin, L-14-II, in complex with lactose at 2.9-A resolution. J. Biol. Chem. 1993, 268, 27034–27038.
61. Collins, P.M.; Bum-Erdene, K.; Yu, X.; Blanchard, H. Galectin-3 Interactions with Glycosphingolipids. J. Mol. Biol. 2014, 426, 1439–1451.
62. Öberg, C.T.; Leffler, H.; Nilsson, U.J. Inhibition of galectins with small molecules. Chimia 2011, 65, 18–23.
63. Pieters, R.J. Inhibition and detection of galectins. Chembiochem 2006, 7, 721–728.
64. van Hattum, H.; Branderhorst, H.M.; Moret, E.E.; Nilsson, U.J.; Leffler, H.; Pieters, R.J. Tuning the preference of thiodigalactoside-and lactosamine-based ligands to galectin-3 over galectin-1. J. Med. Chem. 2013, 56, 1350–1354.
65. Marchiori, M.F.; Souto, D.E.; Bortot, L.O.; Pereira, J.F.; Kubota, L.T.; Cummings, R.D.; Dias-Baruffi, M.; Carvalho, I.; Campo, V.L. Synthetic 1,2,3-triazole-linked glycoconjugates bind with high affinity to human galectin-3. Bioorg. Med. Chem. 2015, 23, 3414–3425.
66. Dam, T.K.; Gabius, H.-J.; André, S.; Kaltner, H.; Lensch, M.; Brewer, C.F. Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants. Biochemistry 2005, 44, 12564–12571.
67. Lundquist, J.J.; Toone, E.J. The cluster glycoside effect. Chem. Rev. 2002, 102, 555–578.
68. Kiessling, L.L.; Young, T.; Gruber, T.D.; Mortell, K.H. Multivalency in protein–carbohydrate recognition. In Glycoscience; Fraser-Reid, B., Tatsuta, K., Thiem, J., Eds.; Springer: Berlin/Heidelberg, Germany, 2008; pp. 2483–2523.
69. Pieters, R.J. Maximising multivalency effects in protein-carbohydrate interactions. Org. Biomol. Chem. 2009, 7, 2013–2025.
70. Pieters, R.J.; Arnusch, C.J.; Breukink, E. Membrane permeabilization by multivalent anti-microbial peptides. Protein Pept. Lett. 2009, 16, 736–742.
71. Lepur, A.; Salomonsson, E.; Nilsson, U.J.; Leffler, H. Ligand induced galectin-3 protein self-association. J. Biol. Chem. 2012, 287, 21751–21756.
72. Goodman, C.K.; Wolfenden, M.L.; Nangia-Makker, P.; Michel, A.K.; Raz, A.; Cloninger, M.J. Multivalent scaffolds induce galectin-3 aggregation into nanoparticles. Beilstein J. Org. Chem. 2014, 10, 1570–1577.
73. Yang, Y.; Xue, X.C.; Jin, X.F.; Wang, L.J.; Sha, Y.L.; Li, Z.J. Synthesis of multivalent N-acetyl lactosamine modified quantum dots for the study of carbohydrate and galectin-3 interactions. Tetrahedron 2012, 68, 7148–7154.
74. Wolfenden, M.; Cousin, J.; Nangia-Makker, P.; Raz, A.; Cloninger, M. Glycodendrimers and modified ELISAs: Tools to elucidate multivalent interactions of galectins 1 and 3. Molecules 2015, 20, 7059–7096.
75. Téllez-Sanz, R.; Garcia-Fuentes, L.; Vargas-Berenguel, A. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr. Med. Chem. 2013, 20, 2979–2990.
76. Hakon, L.; Ulf, J.N. Low-molecular weight inhibitors of galectins. In Galectins and Disease Implications for Targeted Therapeutics; ACS: Washington, DC, USA, 2012; Volume 1115, pp. 47–59.
77. Vrasidas, I.; Andre, S.; Valentini, P.; Bock, C.; Lensch, M.; Kaltner, H.; Liskamp, R.M.; Gabius, H.J.; Pieters, R.J. Rigidified multivalent lactose molecules and their interactions with mammalian galectins: A route to selective inhibitors. Org. Biomol. Chem. 2003, 1, 803–810.
78. André, S.; Sansone, F.; Kaltner, H.; Casnati, A.; Kopitz, J.; Gabius, H.J.; Ungaro, R. Calix[n]arene-based glycoclusters: Bioactivity of thiourea-linked galactose/lactose moieties as inhibitors of binding of medically relevant lectins to a glycoprotein and cell-surface glycoconjugates and selectivity among human adhesion/growth-regulatory galectins. Chembiochem 2008, 9, 1649–1661.
79. André, S.; Grandjean, C.; Gautier, F.M.; Bernardi, S.; Sansone, F.; Gabius, H.J.; Ungaro, R. Combining carbohydrate substitutions at bioinspired positions with multivalent presentation towards optimising lectin inhibitors: Case study with calixarenes. Chem. Commun. 2011, 47, 6126–6128.